Related Experiment Video
Updated: May 15, 2026

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
Published on: January 7, 2019
Pierre Ménétrier and his disease
Robert J Coffey1, Jarred Tanksley
1MRBIV, 2213 Garland Ave, Nashville, TN 37232-0441, USA. robert.coffey@vanderbilt.edu
Abstract:
In 1888, Pierre Ménétrier first described the disease that bears his name. Many of the findings he reported then remain accepted features of the disease. Based on studies performed in our laboratory over the past 20 years, we have implicated increased transforming growth factor-α (TGFα) expression and heightened epidermal growth factor receptor (EGFR) activity in the pathogenesis of Ménétrier's disease. Herein, we provide a historical perspective of this rare disorder, review our experience with Ménétrier's disease, and discuss future challenges and opportunities posed by this disorder.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Lysosomal Hydrolases
Peripheral Artery Disease I: Introduction
Myasthenia Gravis ll: Pathophysiology
Parkinson Disease l: Introduction
Alterations in Muscle Tone lll
